Central nervous system adverse events of immune checkpoint inhibitors.

Abstract

PURPOSE OF REVIEW:

Immune checkpoint inhibitors (ICI) may trigger immune-related adverse events which rarely affect the central nervous system (CNS-irAEs). Over the past few years, cumulative data have led to the characterization of well defined syndromes with distinct cancer and antibody associations as well as different outcomes.

RECENT FINDINGS:

The most frequent CNS-irAE is encephalitis, which includes three main groups: meningoencephalitis, a nonfocal syndrome usually responsive to corticosteroids; limbic encephalitis, associated with high-risk paraneoplastic neurological syndromes (PNS) antibodies (e.g. anti-Hu, anti-Ma2) and neuroendocrine cancers, characterized by poor treatment response and outcomes; and cerebellar ataxia, with variable outcomes (worse when high-risk PNS antibodies are detected). Additionally, a diffuse encephalopathy without inflammatory findings, with poor response to corticosteroids and high mortality has been described. The spectrum of CNS-irAEs also includes meningitis, myelitis, and rarer presentations. A subset of CNS-irAEs (i.e. limbic encephalitis and/or rapidly progressive cerebellar ataxia) is undistinguishable from ICI-naïve PNS.

SUMMARY:

The clinical and outcomes diversity of CNS-irAEs suggests different pathogenic mechanisms, which need to be understood to establish more effective and specific treatment modalities. It is crucial to identify biomarkers able to predict which patients will experience severe CNS-irAEs, to anticipate their diagnosis, and to predict long-term outcomes.

• Authors: Antonio Farina, Macarena Villagrán-García, Alberto Vogrig, Bastien Joubert
• Journal: Current opinion in neurology (Curr Opin Neurol) Vol. 37 Issue 3 Pg. 345-352 (Jun 01 2024) ISSN: 1473-6551 [Electronic] England
• PMID: 38483130 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Humans
• Immune Checkpoint Inhibitors (adverse effects)
• Central Nervous System Diseases (chemically induced, immunology)
• Neoplasms (drug therapy, immunology)